These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 10690940

  • 1. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 2. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P, Heinonen T, Shurzinske L, Black DM.
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [Abstract] [Full Text] [Related]

  • 3. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM.
    JAMA; 1996 Jan 10; 275(2):128-33. PubMed ID: 8531308
    [Abstract] [Full Text] [Related]

  • 6. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM.
    J Clin Lipidol; 2015 Jan 10; 9(1):93-102. PubMed ID: 25670366
    [Abstract] [Full Text] [Related]

  • 7. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H, Diabetes Atorvastatin Lipid intervention (DALI) Study Group.
    Diabetes Care; 2004 Jun 10; 27(6):1358-64. PubMed ID: 15161788
    [Abstract] [Full Text] [Related]

  • 8. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V.
    Biochim Biophys Acta; 2000 Feb 24; 1484(1):29-40. PubMed ID: 10685028
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov 24; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T, Matsuzawa Y.
    Atherosclerosis; 2003 Jun 24; 168(2):359-66. PubMed ID: 12801620
    [Abstract] [Full Text] [Related]

  • 11. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L, Parris W, Adeli K, Cheung RC.
    Metabolism; 2002 Mar 24; 51(3):334-42. PubMed ID: 11887170
    [Abstract] [Full Text] [Related]

  • 12. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2008 Oct 24; 28(10):1831-7. PubMed ID: 18566295
    [Abstract] [Full Text] [Related]

  • 13. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 24; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 14. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
    Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G.
    J Lipid Res; 2017 Jun 24; 58(6):1214-1220. PubMed ID: 28314859
    [Abstract] [Full Text] [Related]

  • 15. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 24; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ.
    J Clin Endocrinol Metab; 2002 Nov 24; 87(11):4991-5000. PubMed ID: 12414863
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
    Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K.
    Metabolism; 2002 Apr 24; 51(4):409-18. PubMed ID: 11912545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.